Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety- and antidepressant-like behavior

Neuropsychopharmacology

Volumn 29, Issue 6, 2004, Pages 1050-1062

  Mombereau, Cedric ^a   Kaupmann, Klemens ^a   Froestl, Wolfgang ^a   Sansig, Gilles ^a   Van Der Putten, Herman ^a   Cryan, John F ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Depression; GABA; GS39783; Mood disorder positive modulator

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; [3 [1 [3 (CYCLOHEXYLMETHYL)HYDROXYPHOSPHINYL] 2 HYDROXYPROPYLAMINO]METHYL]BENZOIC ACID; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CGP 56433A; CHLORDIAZEPOXIDE; DESIPRAMINE; FLUOXETINE; GS 39783; GUANINE NUCLEOTIDE BINDING PROTEIN; N,N' DICYCLOPENTYL 2 METHYLSUFANYL 5 NITROPYRIMIDINE 4,6 DIAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; FORCED SWIMMING TEST; GENETIC ANALYSIS; IMMOBILIZATION; LIGHT DARK CYCLE; LOCOMOTION; LONG TERM CARE; MALE; MAZE TEST; MOUSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BENZOIC ACIDS; CYCLOPENTANES; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HINDLIMB SUSPENSION; MALE; MAZE LEARNING; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MOTOR ACTIVITY; PHOSPHINIC ACIDS; PSYCHOMOTOR PERFORMANCE; PYRIMIDINES; REACTION TIME; RECEPTORS, GABA-B; SWIMMING;

EID: 2442682706     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300413     Document Type: Article

References (82)

1. Abellan MT, Adell A, Honrubia MA, Mengod G, Artigas F (2000a). GABAB-RI receptors in serotonergic neurons: effects of baclofen on 5-HT output in rat brain. Neuroreport 11: 941-945.
2. Abellan MT, Jolas T, Aghajanian GK, Artigas F (2000b). Dual control of dorsal raphe serotonergic neurons by GABA(B) receptors. Electrophysiological and microdialysis studies. Synapse 36: 21-34.
3. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L et al (2002). Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37: 504-508.
4. Andrews N, File SE (1993). Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence. Psychopharmacology (Berl) 112: 21-25.
5. Bai F, Li X, Clay M, Lindstrom T, Skolnick P (2001). Intra- and interstrain differences in models of 'behavioral despair'. Pharmacol Biochem Behav 70: 187-192.
6. Belzung C, Griebel G (2001). Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125: 141-149.
7. Bittiger H, Froestl W, Gentsch C, Jaekel J, Mickel S, Mondadori C et al (1996). GABAB receptor antagonists: potential therapeutic applications. In: Tanaka C, Bowery N (eds). GABA: Receptors, Transporters and Metabolism. Birkhaeuser Verlag: Basel. pp 297-305.
8. Borsini F, Meli A (1988). Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl) 94: 147-160.
9. Borsini F, Podhorna J, Marazziti D (2002). Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163: 121-141.
10. Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M et al (2002). International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol Rev 54: 247-264.
11. Brambilla P, Perez J, Barale F, Schettini G, Soares JC (2003). GABAergic dysfunction in mood disorders. Mol Psychiatry 8: 721-737; 715.
12. Brebner K, Froestl W, Roberts DC (2002). The GABA(B) antagonist CGP56433A attenuates the effect of baclofen on cocaine but not heroin self-administration in the rat. Psychopharmacology (Berl) 160: 49-55.
13. Burman KJ, Ige AO, White JH, Marshall FH, Pangalos MN, Emson PC et al (2003). GABAB receptor subunits, R1 and R2, in brainstem catecholamine and serotonin neurons. Brain Res 970: 35-46.
14. Calver AR, Davies CH, Pangalos M (2002). GABA(B) receptors: from monogamy to promiscuity. Neurosignals 11: 299-314.
15. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA (2002). cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 22: 3262-3268.
16. Costa E (1989). Allosteric modulatory centers of transmitter amino acid receptors. Neuropsychopharmacology 2: 167-174.
17. Crawley JN, Davis LG (1982). Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. Brain Res Bull 8: 609-612.
18. Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA (2001). Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 298: 651-657.
19. Cryan JF, Hoyer D, Markou A (2003a). Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54: 49-58.
20. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van Der Putten H (2003b). Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci 17: 2409-2417.
21. Cryan JF, Leonard BE (2000). 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum Psychopharmacol 15: 113-135.
22. Cryan JF, Markou A, Lucki I (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
23. Cryan JF, Mombereau C (2004). In search of a depressed mouse: models for studying depression-related behavior in genetically mice. Mol Psychiatry, advance online publication, 13 January 2004; doi: 10.1038/sj.mp.4001457.
24. Dalvi A, Rodgers RJ (1996). GABAergic influences on plus-maze behaviour in mice. Psychopharmacology (Berl) 128: 380-397.
25. Dixon AK (1998). Ethological strategies for defence in animals and humans: their role in some psychiatric disorders. Br J Med Psychol 71 (Part 4): 417-445.
26. Drake RG, Davis LL, Cates ME, Jewell ME, Ambrose SM, Lowe JS (2003). Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother 37: 1177-1181.
27. File SE, Zharkovsky A, Gulati K (1991). Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat. Neuropharmacology 30: 183-190.
28. File SE, Zharkovsky A, Hitchcott PK (1992). Effects of nitrendipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 16: 87-93.
29. Froestl W, Mickel SJ, von Sprecher G, Diel PJ, Hall RG, Maier L et al (1995). Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. J Med Chem 38: 3313-3331.
30. Gilbert P, Allan S (1998). The role of defeat and entrapment (arrested flight) in depression: an exploration of an evolutionary view. Psychol Med 28: 585-598.
31. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF (1996). Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54: 129-141.
32. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L et al (2002). Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416: 396-400.
33. Heese K, Otten U, Mathivet P, Raiteri M, Marescaux C, Bernasconi R (2000). GABA(B) receptor antagonists elevate both mRNA and protein levels of the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain and spinal cord of rats. Neuropharmacology 39: 449-462.
34. Holmes A (2001). Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci Biobehav Rev 25: 261-273.
35. Holmes A, Parmigiani S, Ferrari PF, Palanza P, Rodgers RJ (2000). Behavioral profile of wild mice in the elevated plus-maze test for anxiety. Physiol Behav 71: 509-516.
36. Holmes A, Yang RJ, Crawley JN (2002). Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice. J Mol Neurosci 18: 151-165.
37. Jones N, Duxon MS, King SM (2002a). Ethopharmacological analysis of the unstable elevated exposed plus maze, a novel model of extreme anxiety: predictive validity and sensitivity to anxiogenic agents. Psychopharmacology (Berl) 161: 314-323.
38. Jones N, King SM, Duxon MS (2002b). Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a model of extreme anxiety in rats: differential effects of fluoxetine and chlordiazepoxide. Behav Pharmacol 13: 525-535.
39. Ketelaars CE, Bollen EL, Rigter H, Bruinvels J (1988). GABA-B receptor activation and conflict behaviour. Life Sci 42: 933-942.
40. King SM (1999a). Escape-related behaviours in an unstable elevated and exposed environment. I. A new behavioural model of extreme anxiety. Behav Brain Res 98: 113-126.
41. King SM (1999b). Escape-related behaviours in an unstable, elevated and exposed environment. II. Long-term sensitization after repetitive electrical stimulation of the rodent midbrain defence system. Behav Brain Res 98: 127-142.
42. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G et al (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7(Suppl 1): S71-S80.
43. Lapin IP (1995). Only controls: effect of handling, sham injection, and intraperitoneal injection of saline on behavior of mice in an elevated plus-maze. J Pharmacol Toxicol Methods 34: 73-77.
44. Lloyd KG, Morselli PL, Bartholini G (1987). GABA and affective disorders. Med Biol 65: 159-165.
45. Lucki I (2001). A prescription to resist proscriptions for murine models of depression. Psychopharmacology (Berl) 153: 395-398.
46. Lucki I, Dalvi A, Mayorga AJ (2001). Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155: 315-322.
47. Mayorga AJ, Lucki I (2001). Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology (Berl) 155: 110-112.
48. Millan MJ (2003). The neurobiology and control of anxious states. Prog Neurobiol 70: 83-244.
49. Moller HJ (2002). Anxiety associated with comorbid depression. J Clin Psychiatry 63(Suppl 14): 22-26.
50. Nakagawa Y, Ishima T, Ishibashi Y, Tsuji M, Takashima T (1996a). Involvement of GABAB receptor systems in action of antidepressants. II: Baclofen attenuates the effect of desipramine whereas muscimol has no effect in learned helplessness paradigm in rats. Brain Res 728: 225-230.
51. Nakagawa Y, Ishima T, Ishibashi Y, Tsuji M, Takashima T (1996b). Involvement of GABAB receptor systems in experimental depression: baclofen but not bicuculline exacerbates helplessness in rats. Brain Res 741: 240-245.
52. Nakagawa Y, Ishima T, Ishibashi Y, Yoshii T, Takashima T (1996c). Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res 709: 215-220.
53. Nakagawa Y, Sasaki A, Takashima T (1999). The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats. Eur J Pharmacol 381: 1-7.
54. Nastiti K, Benton D, Brain PF (1991). The effects of compounds acting at the benzodiazepine receptor complex on the ultrasonic calling of mouse pups. Behav Pharmacol 2: 121-128.
55. Pick CG, Peter Y, Terkel J, Gavish M, Weizman R (1996). Effect of the neuroactive steroid alpha-THDOC on staircase test behavior in mice. Psychopharmacology (Berl) 128: 61-66.
56. Pilc A, Lloyd KG (1984). Chronic antidepressants and GABA 'B' receptors: a GABA hypothesis of antidepressant drug action. Life Sci 35: 2149-2154.
57. Porsolt RD (2000). Animal models of depression: utility for transgenic research. Rev Neurosci 11: 53-58.
58. Porsolt RD, Bertin A, Jalfre M (1978). 'Behavioural despair' in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 51: 291-294.
59. Prosser HM, Gill CH, Hirst WD, Grau E, Robbins M, Calver A et al (2001). Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice. Mol Cell Neurosci 17: 1059-1070.
60. Queva C, Bremner-Danielsen M, Edlund A, Jonas Ekstrand A, Elg S, Erickson S et al (2003). Effects of GABA agonists on body temperature regulation in GABAB(1)-/- mice. Br J Pharmacol 140: 315-322.
61. Quintero S, Henney S, Lawson P, Mellanby J, Gray JA (1985). The effects of compounds related to gamma-aminobutyrate and benzodiazepine receptors on behavioural responses to anxiogenic stimuli in the rat: punished barpressing. Psychopharmacology (Berl) 85: 244-251.
62. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M et al (1998). Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci USA 95: 14476-14481.
63. Renard CE, Dailly E, David DJ, Hascoet M, Bourin M (2003). Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fund Clin Pharmacol 17: 449-455.
64. Salas R, Pieri F, Fung B, Dani JA, De Biasi M (2003). Altered anxiety-related responses in mutant mice lacking the beta4 subunit of the nicotinic receptor. J Neurosci 23: 6255-6263.
65. Schuler V, Luscher C, Blanchet C, Klix N, Sansig G, Klebs K et al (2001). Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 31: 47-58.
66. Serrats J, Artigas F, Mengod G, Cortes R (2003). GABAB receptor mRNA in the raphe nuclei: co-expression with serotonin transporter and glutamic acid decarboxylase. J Neurochem 84: 743-752.
67. Shephard RA, Wedlock P, Wilson NE (1992). Direct evidence for mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol Biochem Behav 41: 651-653.
68. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994). Behavioural and pharmacological characterisation of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology (Berl) 116: 56-64.
69. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22: 3251-3261.
70. Simiand J, Keane PE, Morre M (1984). The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology (Berl) 84: 48-53.
71. Soudijn W, van Wijngaarden I, IJzerman AP (2002). Allosteric modulation of G protein-coupled receptors. Curr Opin Drug Discov Dev 5: 749-755.
72. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S et al (2000). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295: 1267-1275.
73. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85: 367-370.
74. Stork O, Ji FY, Kaneko K, Stork S, Yoshinobu Y, Moriya T et al (2000). Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res 865: 45-58.
75. Stork O, Yamanaka H, Stork S, Kume N, Obata K (2003). Altered conditioned fear behavior in glutamate decarboxylase 65 null mutant mice. Genes Brain Behav 2: 65-70.
76. Tao R, Ma Z, Auerbach SB (1996). Differential regulation of 5 hydroxytryptamine release by GABAA and GABAB receptors in midbrain raphe nuclei and forebrain of rats. Br J Pharmacol 119: 1375-1384.
77. Tarantino LM, Gould TJ, Druhan JP, Bucan M (2000). Behavior and mutagenesis screens: the importance of baseline analysis of inbred strains. Mamm Genome 11: 555-564.
78. Thierry B, Steru L, Chermat R, Simon P (1984). Searching-waiting strategy: a candidate for an evolutionary model of depression? Behav Neural Biol 41: 180-189.
79. Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W et al (2001). Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2- dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 60: 963-971.
80. Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W et al (2003). N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6- diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther 307: 322-330.
81. van Gaalen MM, Stenzel-Poore MP, Holsboer F, Steckler T (2002). Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci 15: 2007-2015.
82. Weizman R, Paz L, Backer MM, Amiri Z, Modai I, Pick CG (1999). Mouse strains differ in their sensitivity to alprazolam effect in the staircase test. Brain Res 839: 58-65.